Edmond de Rothschild

Welcome to our Fund Center

This site provides extensive information about the ranges of Edmond de Rothschild Group funds. In particular, it provides simplified access to key fund-related data (performance, net asset values, features) and their commercial or legal documents.

Please enter your country and indicate which investor category you belong to:
Mobile Logo

EdR Fund Healthcare Thematic equities

Thematic equities
Change in NAV (23/04/2018)
205.35 USD
Adeline  SALAT-BAROUX–LU1160358047–
Adeline SALAT-BAROUX
Valérie GUELFI–LU1160358047–
Valérie GUELFI
The identity of the managers presented in this document may change during the life of the product.
Risk and reward profile (1)
1234567
Recommended holding period
5 years
205.35 USD
Change in NAV (23/04/2018)
6
1234567
Risk and reward profile
5 years
Recommended holding period
Change in NAV (23/04/2018)
205.35 USD
Risk and reward profile
1234567
Recommended holding period
5 years
Adeline SALAT-BAROUX  
Valérie GUELFI  
The identity of the managers presented in this document may change during the life of the product.
Contact

Investment objective

The objective is to grow net assets by investing in companies operating in the healthcare sector, over the recommended investment period.

View more View less

Commentary 29/03/2018

Renewed market volatility has been confirmed despite the still very strong economic data flow. The US Federal Reserve has upgraded its GDP growth forecast for the United States in 2018. The Fed's new chairman, Jerome Powell, has (as expected) hiked its key interest rate by 0.25% to 1.75%. The healthcare sector was down in March. Large US biotech stocks such as Gilead and Biogen are still under some pressure in a bear market. On the other hand, Shire bounced back on news of Takeda's interest in it. The Japanese pharmaceuticals group has since confirmed its intention to file an offer and must submit this before April 25. Shire's valuation remains very low for the moment, at £35 per share. We are expecting an offer at around £45. Meanwhile, China's 3SBio clocked up March's biggest gain. The company has published annual results that have grown some 31%. Its outlook is strong, driven by sales growth for its existing products and a pipeline of 15 organic products.

View more View less

Change in NAV

Chart – Base 100 (23/04/2018)
Avertissement
You are about to download the historical data for a portfolio. Please note that past performance is not an indication of future performance and it may vary over time. They may be affected, for example, by changes in exchange rates

Performance A-USD Cumulative Annualised
Since 01/01/2018

-2.63 %

-0.18 %

-2.63 %

-0.18 %

1 Year

-0.97 %

11.70 %

-0.96 %

11.63 %

3 Year

-9.80 %

6.51 %

-3.38 %

2.12 %

5 year

36.53 %

60.33 %

6.42 %

9.90 %

Since inception

105.35 %

143.55 %

10.45 %

13.09 %

Since 01/01/2018 1 Year 3 Year 5 year Since inception
Cumulative

Share class (A-USD)

Benchmark

-2.63 %

-0.18 %

-0.97 %

11.70 %

-9.80 %

6.51 %

36.53 %

60.33 %

105.35 %

143.55 %

Annualised

Share class (A-USD)

Benchmark

-0.96 %

11.63 %

-3.38 %

2.12 %

6.42 %

9.90 %

10.45 %

13.09 %

*Rolling periods

Annual performance



Fund information

Inception Date (Fund)
30/04/1985
Inception Date (Part)
28/01/2011
Legal form
SICAV
Benchmark
MSCI AC World Health Care (NR)
Currency (fund)
EUR
Currency (share class)
USD
Distribution Policy
Accumulation
Valuation frequency
Daily
Minimum initial investment
1 Share
ISIN Code
LU1160358047
AuM (fund)
317 M (EUR)
Regulatory authority
CSSF
EU Regulation
UCITS
Management company
Edmond de Rothschild Asset Management (Luxembourg)
Delegated Management Company
Edmond de Rothschild Asset Management (France)
Incorporation
Luxembourg
Maximum management fee
1,700 %
Current management fee
1.700 %
Subscription and redemption conditions
Daily before 12.30 am C.E.T. on day's net asset value
Subscription fee
3.00 % max
Performance fee
15,000 %

Fund documentation

Select all

(1) The rating grades the funds on a scale from 1 to 7. This rating system is based on the average fluctuations of the net asset value over the past five years. It corresponds to the variation range of the portfolio upwards and downwards. If the net asset value is less than 5 years old, the rating is determined by other regulatory calculation methods. Historical data such as those used to calculate the rating may not be a reliable indication of the future risk profile. The current category is neither a guarantee nor an objective. Category 1 does not signify a risk-free investment.

Top